Scotoma Reduction in AMD Patients Treated With Ranibizumab


This is a trial aimed at patients with advanced wet macular degeneration and macular scarring treated wiht intravitreal injections of Lucentis.

Full Title of Study: “A Phase I/II Study to Evaluate Scotoma Reduction in And Limited Visual Acuity in aGe Related Macular Degeneration Patients Treated With Intravitreal Lucentis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2007

Detailed Description

Patients with severe wet macular degeneration and scarring in the center of the retina may benefit from treatment if the size of the blind spot is reduced wiht injections of Lucentis.


  • Drug: intravitreal injection Lucentis (ranibizumab)
    • intravitreal injection Lucentis (ranibizumab)

Clinical Trial Outcome Measures

Primary Measures

  • scotoma reduction
    • Time Frame: 12 months

Secondary Measures

  • improved visual function
    • Time Frame: 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • BCVA < 20/320
  • Disciform macular degeneration wiht exudation

Exclusion Criteria

  • Non-amd CNV

Gender Eligibility: All

Minimum Age: 50 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Retina Research Foundation
  • Provider of Information About this Clinical Study
    • Paul Beer, MD, Retina Consultants, PLLC
  • Overall Official(s)
    • Paul M Beer, MD, Principal Investigator, Retina Research Foundation

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.